hrp0095p1-563 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Transient multiple pituitary hormone deficiency in critically ill pediatric patients

Dror Nitzan , Adam Dganit , Perl Liat , Eliakim Alon

Objective: Hospitalization in pediatric intensive care unit due to critical illness may be life threatening condition associated with severe acute physical stress and concomitant hormonal changes. Whether these changes represent an adaptive response or need to be treated is still not known.Methods: Pituitary hormones evaluation in four patients who were hospitalized in pediatric intensive care unit due to different sever...

hrp0095p1-145 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Spatial navigation and memory in transgender male adolescents treated with gender affirming hormones

Perl Liat , Oren Asaf , C. Mueller Sven , Raphael Ido , Borger Ophir , Sheppes Tamar , Shechner Tomer

Background: Spatial navigation is an essential human skill that helps individuals track their changes in position and orientation by integrating self-motion cues. Meta-analyses indicate that males, on average, perform better than females on a number of spatial tasks. Sex steroids, mainly androgens, modulate the remodeling of synapses in the prefrontal cortex and hippocampus, a limbic brain area with critical influence on spatial and contextual memory. Androgen...

hrp0092p1-265 | Sex Differentiation, Gonads and Gynaecology or Sex Endocrinology (1) | ESPE2019

Dynamics in Blood Pressure After Pubertal Suppression with GnRH Analogs Followed by Testosterone Treatment in Male Adolescents

Perl Liat , Segev-Becker Anat , Israeli Galit , Elkon-Tamir Erella , Weintrob Naomi , Oren Asaf

Background: In 2017, the Endocrine Society published guidelines for the endocrine treatment of gender dysphoria/ gender incongruence. Adolescents who meet diagnostic criteria for gender dysphoria undergo pubertal suppression using gonadotropin-releasing hormone analogs (GnRHa) and induction of puberty with gender-affirming hormonal therapy. Blood pressure (BP) monitoring prior to and during treatment with GnRHa in transgender adolescents is recommended. This r...

hrp0098p2-391 | Late Breaking | ESPE2024

QT Interval Dynamics in Transgender/Gender diverse Adolescents on GnRHa and Gender-Affirming Hormonal Therapy: A Comparative Analysis

Zaitoon Hussein , Kapusta Livia , Israeli Galit , Segev-Becker Anat , Beer Gil , Oren Asaf , Perl Liat

Background: The QT interval, corrected for sex and heart rate (QTc), measures the duration of the cardiac action potential and can indicate the risk of arrhythmias. The QT interval is typically longer in women compared to men; a phenomenon often attributed to estrogen's effects. However, conflicting data exist regarding the effects of gonadotropin-releasing hormone agonist (GnRHa) and gender-affirming hormonal treatment (GAHT) on QT intervals and dispersi...

hrp0095p1-368 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Gender dimorphism in transgender youth – hormonal therapy and the balance between muscle, adipose tissue and cardiometabolic alterations

Borger Ophir , Oren Asaf , Perl Liat , Yackobovitch-Gavan Michal , Sheppes Tamar , Brener Avivit , Elkon-Tamir Erella , Israeli Galit , Segev-Becker Anat , Lebenthal Ophir Yael

Context: Given the importance of sex hormones in metabolic regulation, dynamics in body composition and cardiometabolic alterations may occur in transgender persons receiving gender-affirming hormone (GAH) therapy.Objectives: Our aim was to explore the association between muscle-to-fat ratio (MFR) and the risk for metabolic syndrome components in transgender youth.Methods: In 71 tr...